These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33453702)

  • 21. Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection.
    Dietz J; Kalinina OV; Vermehren J; Peiffer KH; Matschenz K; Buggisch P; Niederau C; Schattenberg JM; Müllhaupt B; Yerly S; Ringelhan M; Schmid RM; Antoni C; Müller T; Schulze Zur Wiesch J; Piecha F; Moradpour D; Deterding K; Wedemeyer H; Moreno C; Berg T; Berg CP; Zeuzem S; Welsch C; Sarrazin C;
    J Viral Hepat; 2020 Oct; 27(10):974-986. PubMed ID: 32396998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
    McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolution and persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures.
    Jeong Y; Jin B; Lee HW; Park HJ; Park JY; Kim DY; Han KH; Ahn SH; Kim S
    J Viral Hepat; 2018 Nov; 25(11):1251-1259. PubMed ID: 29768695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NS5A resistance - associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey.
    Sayan M; Yıldırım FS; Akhan S; Yıldırım AA; Şirin G; Cabalak M; Demir M; Can S; Ersöz G; Altıntaş E; Ensaroğlu F; Akbulut A; Şener A; Deveci A
    Int J Infect Dis; 2020 Jun; 95():84-89. PubMed ID: 32302766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life data.
    Gozlan Y; Bucris E; Shirazi R; Rakovsky A; Ben-Ari Z; Davidov Y; Veizman E; Saadi T; Braun M; Cohen-Naftaly M; Shlomai A; Shibolet O; Zigmond E; Katchman H; Menachem Y; Safadi R; Galun E; Zuckerman E; Nimer A; Hazzan R; Maor Y; Saif AM; Etzion O; Lurie Y; Mendelson E; Mor O
    Antivir Ther; 2019; 24(3):221-228. PubMed ID: 30880684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing.
    Nguyen T; Akhavan S; Caby F; Bonyhay L; Larrouy L; Gervais A; Lebray P; Poynard T; Calmus Y; Simon A; Valantin MA; Calvez V; Marcelin AG; Todesco E
    Int J Antimicrob Agents; 2019 Jan; 53(1):80-83. PubMed ID: 30236959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.
    Fernandez-Antunez C; Wang K; Fahnøe U; Mikkelsen LS; Gottwein JM; Bukh J; Ramirez S
    Hepatology; 2023 Aug; 78(2):621-636. PubMed ID: 36999539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan.
    Hong CM; Lin YY; Liu CJ; Lai YY; Yeh SH; Yang HC; Kao JH; Hsu SJ; Huang YH; Yang SS; Kuo HT; Cheng PN; Yu ML; Chen PJ
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals.
    Howe AYM; Rodrigo C; Cunningham EB; Douglas MW; Dietz J; Grebely J; Popping S; Sfalcin JA; Parczewski M; Sarrazin C; de Salazar A; Fuentes A; Sayan M; Quer J; Kjellin M; Kileng H; Mor O; Lennerstrand J; Fourati S; Di Maio VC; Chulanov V; Pawlotsky JM; Harrigan PR; Ceccherini-Silberstein F; Garcia F;
    JHEP Rep; 2022 May; 4(5):100462. PubMed ID: 35434589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1.
    Costa VD; Delvaux N; Brandão-Mello CE; Nunes EP; de Sousa PSF; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC
    Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):700-706. PubMed ID: 30880098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular characterization of hepatitis C virus for subtype determination and resistance-associated substitutions detection among Chinese voluntary blood donors.
    Jiang X; Lv X; Chang L; Yan Y; Ji H; Sun H; Guo F; Rodgers MA; Yin P; Wang L
    Antiviral Res; 2020 Sep; 181():104871. PubMed ID: 32717286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection.
    Esposito I; Marciano S; Haddad L; Galdame O; Franco A; Gadano A; Flichman D; Trinks J
    Viruses; 2018 Dec; 11(1):. PubMed ID: 30577623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutational spectrum of hepatitis C virus in patients with chronic hepatitis C determined by single molecule real-time sequencing.
    Nakamura F; Takeda H; Ueda Y; Takai A; Takahashi K; Eso Y; Arasawa S; Iguchi E; Shimizu T; Mishima M; Kumagai K; Yamashita T; Uemoto S; Kato N; Marusawa H; Sekine A; Seno H
    Sci Rep; 2022 Apr; 12(1):7083. PubMed ID: 35490163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline NS5A resistance associated substitutions may impair DAA response in real-world hepatitis C patients.
    Carrasco I; Arias A; Benítez-Gutiérrez L; Lledó G; Requena S; Cuesta M; Cuervas-Mons V; de Mendoza C
    J Med Virol; 2018 Mar; 90(3):532-536. PubMed ID: 28990680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients.
    Aldunate F; Echeverría N; Chiodi D; López P; Sánchez-Cicerón A; Fajardo A; Soñora M; Cristina J; Hernández N; Moreno P
    Dis Markers; 2018; 2018():2514901. PubMed ID: 30186532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy.
    Kileng H; Kjellin M; Akaberi D; Bergfors A; Duberg AS; Wesslén L; Danielsson A; Gangsøy Kristiansen M; Gutteberg T; Goll R; Lannergård A; Lennerstrand J
    Scand J Gastroenterol; 2018; 53(10-11):1347-1353. PubMed ID: 30394152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HCV resistance-associated substitutions following direct-acting antiviral therapy failure - Real-life data from Poland.
    Parczewski M; Janczewska E; Pisula A; Dybowska D; Łojewski W; Witor A; Wawrzynowicz-Syczewska M; Socha Ł; Krygier R; Knysz B; Musialik J; Urbańska A; Scheibe K; Jaroszewicz J
    Infect Genet Evol; 2021 Sep; 93():104949. PubMed ID: 34087494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Features of resistance-associated substitutions after failure of multiple direct-acting antiviral regimens for hepatitis C.
    Itakura J; Kurosaki M; Kakizaki S; Amano K; Nakayama N; Inoue J; Endo T; Marusawa H; Hasebe C; Joko K; Wada S; Akahane T; Koushima Y; Ogawa C; Kanto T; Mizokami M; Izumi N
    JHEP Rep; 2020 Oct; 2(5):100138. PubMed ID: 32817930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs.
    Paolucci S; Premoli M; Novati S; Gulminetti R; Maserati R; Barbarini G; Sacchi P; Piralla A; Sassera D; De Marco L; Girello A; Mondelli MU; Baldanti F
    Sci Rep; 2017 Nov; 7(1):16017. PubMed ID: 29167469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.